Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Depreciation & Amortization (CF) (2019 - 2025)

AVITA Medical (RCEL) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $700000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 71.15% year-over-year to $700000.0, compared with a TTM value of $2.3 million through Dec 2025, up 108.44%, and an annual FY2025 reading of $2.3 million, up 108.44% over the prior year.
  • Depreciation & Amortization (CF) was $700000.0 for Q4 2025 at AVITA Medical, up from $574000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $700000.0 in Q4 2025 and bottomed at $130000.0 in Q4 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $292062.5, with a median of $195000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) dropped 17.18% in 2023, then soared 170.59% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $130000.0 in 2022, then soared by 43.85% to $187000.0 in 2023, then surged by 118.72% to $409000.0 in 2024, then soared by 71.15% to $700000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for RCEL at $700000.0 in Q4 2025, $574000.0 in Q3 2025, and $552000.0 in Q2 2025.